The mothers, Omega-3 and mental health study

University of Michigan, Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Ann Arbor, Michigan, USA.
BMC Pregnancy and Childbirth (Impact Factor: 2.19). 06/2011; 11(1):46. DOI: 10.1186/1471-2393-11-46
Source: PubMed


Major depressive disorder (MDD) during pregnancy and postpartum depression are associated with significant maternal and neonatal morbidity. While antidepressants are readily used in pregnancy, studies have raised concerns regarding neurobehavioral outcomes in exposed infants. Omega-3 fatty acid supplementation, most frequently from fish oil, has emerged as a possible treatment or prevention strategy for MDD in non-pregnant individuals, and may have beneficial effects in pregnant women. Although published observational studies in the psychiatric literature suggest that maternal docosahexaenoic acid (DHA) deficiency may lead to the development of MDD in pregnancy and postpartum, there are more intervention trials suggesting clinical benefit for supplementation with eicosapentaenoic acid (EPA) in MDD.
The Mothers, Omega-3 and Mental Health study is a double blind, placebo-controlled, randomized controlled trial to assess whether omega-3 fatty acid supplementation may prevent antenatal and postpartum depressive symptoms among pregnant women at risk for depression. We plan to recruit 126 pregnant women at less than 20 weeks gestation from prenatal clinics at two health systems in Ann Arbor, Michigan and the surrounding communities. We will follow them prospectively over the course of their pregnancies and up to 6 weeks postpartum. Enrolled participants will be randomized to one of three groups: a) EPA-rich fish oil supplement (1060 mg EPA plus 274 mg DHA) b) DHA-rich fish oil supplement (900 mg DHA plus 180 mg EPA; or c) a placebo. The primary outcome for this study is the Beck Depression Inventory (BDI) score at 6 weeks postpartum. We will need to randomize 126 women to have 80% power to detect a 50% reduction in participants' mean BDI scores with EPA or DHA supplementation compared with placebo. We will also gather information on secondary outcome measures which will include: omega-3 fatty acid concentrations in maternal plasma and cord blood, pro-inflammatory cytokine levels (IL-1β, IL-6, and TNF-α) in maternal and cord blood, need for and dosage of antidepressant medications, and obstetrical outcomes. Analyses will be by intent to treat.
This study compares the relative effectiveness of DHA and EPA at preventing depressive symptoms among pregnant women at risk.
Clinical trial registration number: NCT00711971.

Download full-text


Available from: Delia M Vázquez
  • Source
    • "Some reliable data suggest that n-6 PUFAs are also involved in depression. However, in contrast to n-3 PUFAs that have been inversely associated with depressive symptoms (Sublette et al. 2011; Mozurkewich et al. 2011; Hibbeln 1998), a positive correlation has been reported for n-6 PUFAs and the high ratio of n-6/n-3 (Mamalakis et al. 2006; Kiecolt-Glaser et al. 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Polyunsaturated fatty acids play an important role in the human organism. They guarantee a normal function of nervous cells, influence neurotransmission, and build some elements of cellular membranes. Several reports indicate an association between a deficiency of polyunsaturated fatty acids and depression. The aim of this study was to examine the effects of diet supplemented with fish oil, which is rich in omega-3 polyunsaturated fatty acids (n-3 PUFAs) and n-3 PUFAs enriched phospholipids ("super lecithin") obtained from designed eggs on anhedonic-like response and body weight in the rat chronic mild stress (CMS) model of depression. The results showed that neither fish oil nor n-3 PUFAs enriched egg yolk phospholipids supplementation reversed disturbances caused by CMS, such as anhedonic-like state or reduction of body weight gain.
    Full-text · Article · Aug 2013 · Pharmazie
  • [Show abstract] [Hide abstract]
    ABSTRACT: The omega-3 fatty acid, docosahexaenoic acid, is an important building block of the CNS, and its availability during pregnancy and lactation may influence maternal mental health and, later, childhood developmental outcomes. Epidemiological and observational studies have supported a role for omega-3 fatty acids in optimizing child development and maternal mental health. However, results of randomized intervention studies have not consistently shown beneficial effects for omega-3 fatty acid supplementation during pregnancy and lactation. This review summarizes the biological plausibility, as well as the available evidence from observational and randomized controlled trials, of omega-3 supplementation in pregnancy and lactation.
    No preview · Article · Feb 2012 · Clinical Lipidology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Prevention aims to avoid the occurrence of psychiatric illness and disability caused by psychic disorders. The relevant interventions refer to the individual, the family context and other environmental factors. Universal and primary prevention target the entire population or a part of this (i. e. students). Secondary and selective intervention should prevent the manifestation of psychiatric disorders in vulnerable individuals (i. e. children with behavioral problems). Tertiary measures aim at preventing the worsening or recurrence of symptoms in individuals who already suffer from mental illness. Within the past 25 years protective and risk factors that reduce or increase the probability of occurrence of mental disorders have increasingly been identified. This results in improved prevention. The present article gives an overview of preventive measures against the most common mental disorders in the light of the current evidence base.
    No preview · Article · Jun 2012 · DMW - Deutsche Medizinische Wochenschrift
Show more